Heike S.
- Country
- Germany
- Department
- N/A
Research Overview
- J3L-MC-EZEB: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults with Elevated Lipoprotein(a)
- J2A-MC-GZGQ: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
- Evaluation of AZD9550 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Overweight and Obese Patients with Non-alcoholic Steatohepatitis
Data & Insights
Has run more than one trial at 11 of 149 partner sites.
Specializations
Metabolic Disorders
This investigator specializes in treating complex metabolic conditions, with particular emphasis on Type 2 Diabetes and its intersection with obesity management.
- Weight Management Therapeutics
- Glucose Control Interventions
- Metabolic Disease Management
Their research encompasses innovative therapeutic approaches for patients with combined metabolic conditions.
Cardiovascular Health
The investigator focuses on addressing cardiovascular risks in metabolic patients, particularly exploring treatments for lipoprotein disorders and cardiovascular complications.
- Cardiovascular Risk Prevention
- Lipid Management
- Cardiometabolic Interventions
Their work integrates cardiovascular health considerations with metabolic disease treatment strategies.
Hepatic Conditions
The investigator conducts research in liver-related metabolic conditions, with specific attention to non-alcoholic steatohepatitis and its relationship with obesity.
- Hepatic Disease Management
- Metabolic Liver Conditions
- Novel Therapeutic Approaches
Their research explores the connections between metabolic disorders and liver health outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.